Vaxart Disappoints With Coronavirus Vaccine Trial Update

Vaxart (NASDAQ: VXRT) has seemingly fallen further behind in the coronavirus vaccine race. On Monday, the company unveiled preliminary data from a phase 1 study of its vaccine candidate, VXA-CoV2-1, that showed a potentially significant weakness.The company reported that its oralRead MoreMarketsMarkets Feed